Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-dose tamoxifen in breast cancer bone metastasis.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2013
Same author

Maintenance chemotherapy or not in ovarian cancer stages IIIA, B, C, and IV after disease recurrence.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2013
Same author

Combination of three cytotoxic agents in small-cell lung cancer.

Cancer chemotherapy and pharmacology·2012
Same author

Two consecutive days of treatment with liposomal cisplatin in non-small cell lung cancer.

Oncology letters·2012
Same author

Erlotinib treatment in pretreated patients with non-small cell lung cancer: A Phase II study.

Oncology letters·2012
Same author

Plasma VEGF levels in breast cancer patients with and without metastases.

Oncology letters·2012
Same journal

Vitamin C through upregulating SYNPO2 level suppresses the proliferation and migration of glioma cells.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2021
Same journal

Some concerns about clinical-pathological characteristics of breast cancer cases detected by chest computed tomography.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2021
Same journal

SARS-CoV-2 infection in breast carcinoma patients.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2021
Same journal

Preference of trastuzumab emtansine as a second or third line treatment in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer refractory to trastuzumab and pertuzumab.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2021
Same journal

Taxane use for breast cancer-related lymphoedema risk.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2021
Same journal

The place of Omalizumab in the treatment of Carboplatin hypersensitivity.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology·2021
See all related articles

Related Experiment Video

Updated: May 7, 2026

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

Cisplatin: process and future.

G P Stathopoulos1

  • 1First Oncology Clinic, Errikos Dunant Hospital, Athens, Greece.

Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology
|September 26, 2013
PubMed
Summary
This summary is machine-generated.

Cisplatin (CDDP) is a key anticancer drug for non-small-cell lung cancer (NSCLC). A new liposomal cisplatin formulation offers reduced toxicity and equal or greater effectiveness, especially for lung adenocarcinoma.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Related Experiment Videos

Last Updated: May 7, 2026

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Development

Background:

  • Cisplatin (CDDP) has been a cornerstone in non-small-cell lung cancer (NSCLC) treatment for decades.
  • While effective, CDDP is associated with significant nephrotoxicity and other side effects.
  • Alternative agents like carboplatin and taxanes were introduced to mitigate toxicity, but without improving efficacy.

Purpose of the Study:

  • To evaluate the efficacy and toxicity profile of a novel liposomal cisplatin formulation.
  • To compare the effectiveness of liposomal cisplatin against standard CDDP, particularly in lung adenocarcinoma.
  • To assess the potential of liposomal cisplatin to overcome the limitations of conventional CDDP therapy.

Main Methods:

  • Review of existing studies on cisplatin-based chemotherapy for NSCLC.
  • Analysis of data from clinical trials investigating liposomal cisplatin formulations.
  • Comparative assessment of efficacy and toxicity data between standard CDDP and liposomal cisplatin.

Main Results:

  • Liposomal cisplatin demonstrates significantly reduced toxicity, notably eliminating nephrotoxicity.
  • The novel formulation shows comparable effectiveness to standard CDDP in general NSCLC treatment.
  • Liposomal cisplatin exhibits higher effectiveness than standard CDDP specifically in lung adenocarcinoma cases.

Conclusions:

  • Liposomal cisplatin represents a promising advancement in NSCLC therapy, offering a better safety profile.
  • This formulation maintains the therapeutic value of cisplatin while minimizing adverse effects.
  • Liposomal cisplatin holds particular potential for improving outcomes in patients with lung adenocarcinoma.